Quantcast

Latest Diagnostic tests Stories

2010-06-06 07:00:00

SAN DIEGO, June 6 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago. On June 5(th), scientists from...

2010-06-04 01:01:00

BEIJING, June 4 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced its unaudited financial results for the fourth fiscal quarter ("4Q FY2009") and the full fiscal year ended March 31, 2010 ("FY2009"). 4Q FY2009 Highlights -- Revenues decreased by 29.3% year-over-year to RMB175.7 million (US$25.7 million) but increased by 2.0% sequentially....

2010-04-13 08:15:00

DENVER, April 13 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, including innovative products for emerging pathogens and lethal viruses, today announced a major extension of the collaborative effort to combat important viral diseases. The National Institutes of Health (NIH) has awarded a grant totaling $600,000 to Corgenix for the two-year study, which will focus on development of novel,...

2010-04-12 05:30:00

QUEBEC CITY and WEST CHESTER, PA, April 12 /PRNewswire-FirstCall/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, has appointed Ms. Valerie Palmieri as President of DiagnoCure Oncology Laboratories, the U.S. subsidiary of DiagnoCure, Inc. Ms. Palmieri brings to DiagnoCure more than 25 years of experience in the laboratory industry, including executive positions responsible for laboratory services,...

2010-03-17 13:30:00

QUEBEC CITY, March 17 /PRNewswire-FirstCall/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the first quarter 2010 ended January 31, 2010. The Company announced a net loss of $3,820,089 or $0.09 per share for the first quarter 2010. These results are substantially in line with Management's expectations; they reflect activities undertaken during this...

2010-03-04 07:00:00

SAN DIEGO, Calif., March 4 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing. CancerTYPE ID predicts cancer origin in patients whose primary cancer was initially "unknown or uncertain" using conventional diagnostics. Knowing the site...

2010-02-15 09:22:00

- Taking Steps to Preserve Liquidity - QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, today announced changes to its enterprise structure to optimize its growth potential. Henceforth, the Company will be comprised of two business segments: (1) administrative headquarters in Quebec City, holder of the PCA3, GCC and Shc patents, and (2)...

2010-02-09 07:30:00

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). (Logo:...

2010-01-14 16:44:00

QUEBEC CITY, Jan. 14 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, today reported financial and operation results for the fourth quarter 2009 and fiscal year ended October 31, 2009. The Company announced a net loss of $2,680,018 or $0.07 per share for the fourth quarter ending October 31, 2009, and a net loss of $12,865,055 or $0.30 per share for the fiscal year 2009. These results...

2010-01-11 07:00:00

SAN DIEGO, Jan. 11 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announced that the company has signed a three-year, exclusive agreement with Ferrer inCode to commercialize the bioTheranostics THEROS CancerTYPE ID® molecular cancer classifier in Spain, Portugal, Greece, and Venezuela. The agreement is effective immediately. Under the terms of the agreement, Spain-based...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related